Richard J. Reitemeier, M.D., F.A.C.P.; Charles G. Moertel, M.D., F.A.C.P.; Richard G. Hahn, M.D.
This content is PDF only. Please click on the PDF icon to access.
In excess of 500 patients with far-advanced adenocarcinoma of gastrointestinal tract origin have received palliative treatment with one or more chemotherapeutic agents. Nine separate protocols have been used with objective remissions determined by significant decrease in size of measurable lesions known to contain carcinoma. The following remission rate occurred:
Fluorinated pyrimidine therapy: 5-FU study of slow versus rapid administration: rapid, 9/45 (20%), slow, 5/45 (11%); 5-FU versus 5-FUDR study: 5-FU, 10/84 (12%), 5-FUDR, 19/84 (23%); oxylone-5-FU study (data as of October, 1964. Additional cases will be reported in March, 1965.) oxylone alone, 3/26 (12%); 5-FU alone, 3/32 (9%), oxylone and
Reitemeier RJ, Moertel CG, Hahn RG. Palliative Therapy of Advanced Gastrointestinal Adenocarcinoma.. Ann Intern Med. ;62:1081. doi: 10.7326/0003-4819-62-5-1081_1
Download citation file:
Published: Ann Intern Med. 1965;62(5):1081.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use